Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Dysport vs Masport botulinum toxin for pain relief in trigeminal neuralgia
IRCT20210306050606N3Phase 2Completed
- Sponsor
- Shahid Sadoughi University of Medical Sciences
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of botulinum toxin type A and abobotulinumtoxinA in trigeminal neuralgia (TN) (2 arms), sponsored by Shahid Sadoughi University of Medical Sciences. Primary endpoint: Pain improvement. Started Dec 2025; status: completed.
02
Drugs
botulinum toxin type AabobotulinumtoxinA
03
Conditions
trigeminal neuralgia (TN)
Beyond the preview
Go deeper on IRCT20210306050606N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210306050606N3.